Bardoxolone methyl (also known as “RTA 402” and “CDDO-methyl ester”) is an orally-available first-in-class synthetic triterpenoid belonging to the antioxidant inflammation modulator (AIM) class. It is the most potent known inducer of the Nrf2 pathway to enter clinical development and works to suppress both oxidative stress and inflammation. Bardoxolone methyl is currently being developed by Reata Pharmaceuticals, Inc. in partnership with Abbott Laboratories and Kyowa Hakko Kirin, for the treatment of advanced chronic kidney disease (CKD) in type 2 diabetes mellitus patients.
仅供研究使用。 我们不向患者出售。
名称 | Bardoxolone methyl |
---|---|
Iupac 化学名称 | (4aS,6aR,6bS,12aS,14aR,14bR)-methyl 11-cyano-2,2,6a,6b,9,9,12a-heptamethyl-10,14-dioxo-1,2,3,4,4a,5,6,6a,6b,7,8,8a,9,10,12a,14,14a,14b-octadecahydropicene-4a-carboxylate |
同义词 | CDDO Methyl ester; CDDO-Me; NSC 713200; RTA 402; RTA402; RTA-402 |
英文同义词 | CDDO Methyl ester; CDDO-Me; NSC 713200; RTA 402; RTA402; RTA-402 |
分子式 | C32H43NO4 |
分子量 | 505.69 |
Smile | C(#N)C=1C(C(C2CC[C@]3([C@@]4(CC[C@]5(CCC(C[C@@H]5[C@H]4C(C=C3[C@]2(C1)C)=O)(C)C)C(=O)OC)C)C)(C)C)=O |
InChiKey | WPTTVJLTNAWYAO-OROHISIGSA-N |
InChi | InChI=1S/C32H43NO4/c1-27(2)11-13-32(26(36)37-8)14-12-31(7)24(20(32)17-27)21(34)15-23-29(5)16-19(18-33)25(35)28(3,4)22(29)9-10-30(23,31)6/h15-16,20,22,24H,9-14,17H2,1-8H3/t20-,22?,24+,29+,30-,31-,32+/m1/s1 |
Cas号 | 218600-53-4 |
相关CAS号 |
包装 | 价格 | 库存 | 纯度 | 备货期 |
---|---|---|---|---|
大货 | 询价 | 询价 | 询价 |